Big Break in Fighting Melanoma

February 1, 2011


Ravi Amaravadi, MD, an assistant professor in the division of Hematology/Oncology, is quoted in a 6ABC story about a new drug, known as RG7204, which is showing an unprecedented efficacy in patients with metastatic melanoma whose tumors carry a mutation called BRAF. Although existing treatments for the disease help only a small number of patients, among those taking the new drug, "about 80 percent of patients benefited in some way with some form of tumor shrinkage." Based on positive trial results, the drug has recently become available for compassionate use in patients newly diagnosed with the disease and to those who were initially randomized to the control arm of the trial. View this story

Additional Coverage

Lynn Schuchter, MD, chief of the division of Hematology/Oncology, is featured in a Medstar TV story about the promising melanoma drug known as RG7204 that aired in more than a dozen cities across the United States. An Abramson Cancer Center patient is also featured. View Segment

Related Information